Abstract:α -Synuclein ( α -Syn) aggregation in Lewy bodies and Lewy neurites has emerged as a key pathogenetic feature in Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Various factors, including posttranslational modifications (PTMs), can influence the propensity of α -Syn to misfold and aggregate. PTMs are biochemical modifications of a protein that occur during or after translation and are typically mediated by enzymes. PTMs modulate several characteristics of proteins including their structure, activity, localization, and stability. α -Syn undergoes various posttranslational modifications, including phosphorylation, ubiquitination, SUMOylation, acetylation, glycation, O-GlcNAcylation, nitration, oxidation, polyamination, arginylation, and truncation. Different PTMs of a protein can physically interact with one another or work together to influence a particular physiological or pathological feature in a process known as PTMs crosstalk. The development of detection techniques for the cooccurrence of PTMs in recent years has uncovered previously unappreciated mechanisms of their crosstalk. This has led to the emergence of evidence supporting an association between α -Syn PTMs crosstalk and synucleinopathies. In this review, we provide a comprehensive evaluation of α -Syn PTMs, their impact on misfolding and pathogenicity, the pharmacological means of targeting them, and their potential as biomarkers of disease. We also highlight the importance of the crosstalk between these PTMs in α -Syn function and aggregation. Insight into these PTMS and the complexities of their crosstalk can improve our understanding of the pathogenesis of synucleinopathies and identify novel targets of therapeutic potential. Significance Statement α -Synuclein is a key pathogenic protein in Parkinson's disease and other synucleinopathies, making it a leading therapeutic target for disease modification. Multiple posttranslational modifications occur at various sites in α -Synuclein and alter its biophysical and pathological properties, some interacting with one another to add to the complexity of the pathogenicity of this protein. This review details these modifications, their implications in disease, and potential therapeutic opportunities.

Author Correction: Post-translational Modifications of Soluble Α-Synuclein Regulate the Amplification of Pathological Α-Synuclein

Mechanistic basis for receptor-mediated pathological α-synuclein fibril cell-to-cell transmission in Parkinson's disease

Exploring the Roles of Post-Translational Modifications in the Pathogenesis of Parkinson's Disease Using Synthetic and Semisynthetic Modified Α-Synuclein.

Exploring the role of post‐translational modifications in regulating α‐synuclein interactions by studying the effects of phosphorylation on nanobody binding

Posttranslational Modifications Ofα-Synuclein, Their Therapeutic Potential, and Crosstalk in Health and Neurodegenerative Diseases

The Roles of Post-translational Modifications on Α-Synuclein in the Pathogenesis of Parkinson’s Diseases

Posttranslational Modifications of {alpha}-Synuclein, Their Therapeutic Potential, and Crosstalk in Health and Neurodegenerative Diseases

Phosphorylation and O-GlcNAcylation at the Same Α-Synuclein Site Generate Distinct Fibril Structures

β-synuclein regulates the phase transitions and amyloid conversion of α-synuclein

Leucine Carboxyl Methyltransferase Downregulation and Protein Phosphatase Methylesterase Upregulation Contribute Toward the Inhibition of Protein Phosphatase 2A by α-Synuclein

1 serine 129 phosphorylation reduces α-synuclein ’ s ability to regulate tyrosine hydroxylase and protein phosphatase 2 a in vitro and in vivo

Enzymatic O-GlcNAcylation of Α-Synuclein Reduces Aggregation and Increases SDS-resistant Soluble Oligomers

Elucidating the Role of C-terminal Post-Translational Modifications Using Protein Semisynthesis Strategies: Α-Synuclein Phosphorylation at Tyrosine 125.

In silico analysis of alpha‐synuclein protein variants and posttranslational modifications related to Parkinson's disease

-Synuclein phase separation and amyloid aggregation are modulated by C-terminal truncations

Low-density lipoprotein receptor-related protein 1 mediates α-synuclein transmission from the striatum to the substantia nigra in animal models of Parkinson's disease

Endogenous Alpha-Synuclein is Essential for the Transfer of Pathology by Exosome-Enriched Extracellular Vesicles, Following Inoculation with Preformed Fibrils in vivo

Alpha-synuclein phosphorylation induces amyloid conversion via enhanced electrostatic bridging: Insights from molecular modeling of the full-length protein

Phosphorylation Induces Distinct Alpha-Synuclein Strain Formation

Altered Conformation of Α-Synuclein Drives Dysfunction of Synaptic Vesicles in a Synaptosomal Model of Parkinson's Disease.

Α‐synuclein Stimulation of Monoamine Oxidase‐b and Legumain Protease Mediates the Pathology of Parkinson's Disease